SEC Form 4 · accession 0000899243-16-033607
Sorrento Therapeutics, Inc. · SRNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jerome B Zeldis
Officer — See Remarks
Period of report
Aug 12, 2016
Accepted (ET)
Nov 15, 2016 · 7:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000850261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $6.52 | Aug 12, 2016 | A | 200,000 | A | — | Aug 12, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F11/4 of the original number of shares subject to the option shall vest on August 12, 2017 and 1/48 of the original number of shares subject to the option shall vest following each one month period of service after August 12, 2017, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Remarks
Chief Medical Officer and President of Clinical Development